

Steven Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5998345/publications.pdf>

Version: 2024-02-01

55
papers

1,960
citations

279798

23
h-index

254184

43
g-index

55
all docs

55
docs citations

55
times ranked

2986
citing authors

#	ARTICLE	IF	CITATIONS
1	Essential medicines for universal health coverage. <i>Lancet, The</i> , 2017, 389, 403-476.	13.7	366
2	The effect of cost on adherence to prescription medications in Canada. <i>Cmaj</i> , 2012, 184, 297-302.	2.0	182
3	Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. <i>CMAJ Open</i> , 2016, 4, E346-E351.	2.4	88
4	“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada. <i>BMJ: British Medical Journal</i> , 2005, 331, 815-816.	2.3	82
5	Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. <i>BMJ Open</i> , 2017, 7, e014287.	1.9	82
6	Estimated cost of universal public coverage of prescription drugs in Canada. <i>Cmaj</i> , 2015, 187, 491-497.	2.0	73
7	Pricing of pharmaceuticals is becoming a major challenge for health systems. <i>BMJ, The</i> , 2020, 368, l4627.	6.0	68
8	Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. <i>Health Policy</i> , 2017, 121, 354-362.	3.0	67
9	Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. <i>Age and Ageing</i> , 2016, 45, 535-542.	1.6	60
10	The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey. <i>CMAJ Open</i> , 2018, 6, E63-E70.	2.4	57
11	Postmarket policy considerations for biosimilar oncology drugs. <i>Lancet Oncology, The</i> , 2016, 17, e31-e38.	10.7	55
12	Sex Disparities in Post-Acute Myocardial Infarction Pharmacologic Treatment Initiation and Adherence. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 586-592.	2.2	47
13	Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare. <i>Journal of Pharmaceutical Policy and Practice</i> , 2018, 11, 28.	2.4	47
14	Universal prescription drug coverage in Canada. <i>Healthcare Management Forum</i> , 2016, 29, 247-254.	1.4	43
15	Effect on Treatment Adherence of Distributing Essential Medicines at No Charge. <i>JAMA Internal Medicine</i> , 2020, 180, 27.	5.1	41
16	Both New and Chronic Potentially Inappropriate Medications Continued at Hospital Discharge Are Associated With Increased Risk of Adverse Events. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1184-1192.	2.6	38
17	Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. <i>Obstetrics and Gynecology</i> , 2016, 127, 553-561.	2.4	37
18	Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage. <i>Cmaj</i> , 2017, 189, E794-E799.	2.0	36

#	ARTICLE	IF	CITATIONS
19	International Best Practices For Negotiating “Reimbursement Contracts” With Price Rebates From Pharmaceutical Companies. <i>Health Affairs</i> , 2013, 32, 771-777.	5.2	32
20	Understanding the patient experience of cost-related non-adherence to prescription medications through typology development and application. <i>Social Science and Medicine</i> , 2017, 194, 51-59.	3.8	30
21	Seniors’ prescription drug cost inflation and cost containment: evidence from British Columbia. <i>Health Policy</i> , 2004, 68, 299-307.	3.0	26
22	Postpartum domperidone use in British Columbia: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E13-E19.	2.4	25
23	The association between domperidone and ventricular arrhythmia in the postpartum period. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1210-1214.	1.9	25
24	Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada. <i>Cmaj</i> , 2017, 189, E295-E302.	2.0	24
25	Determinants of trends in prescription opioid use in British Columbia, Canada, 2005–2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 553-559.	1.9	23
26	Trends and sex differences in prescription opioid deaths in British Columbia, Canada. <i>Injury Prevention</i> , 2016, 22, 288-290.	2.4	21
27	New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines. <i>BMJ</i> , 2020, 368, l4408.	6.0	20
28	The economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare?. <i>Journal of Health Services Research and Policy</i> , 2003, 8, 237-244.	1.7	19
29	Sensitivity and specificity of administrative mortality data for identifying prescription opioid-related deaths. <i>Cmaj</i> , 2016, 188, E67-E72.	2.0	19
30	Long-term sedative use among community-dwelling adults: a population-based analysis. <i>CMAJ Open</i> , 2017, 5, E52-E60.	2.4	19
31	Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. <i>Health Policy</i> , 2013, 112, 248-254.	3.0	18
32	Patterns and trends in long-term opioid use for non-cancer pain in British Columbia, 2005–2012. <i>Canadian Journal of Public Health</i> , 2016, 107, e404-e409.	2.3	16
33	Failure to follow medication changes made at hospital discharge is associated with adverse events in 30 days. <i>Health Services Research</i> , 2020, 55, 512-523.	2.0	15
34	Evaluating the effects of Quebec’s private–public drug insurance system. <i>Cmaj</i> , 2017, 189, E1259-E1263.	2.0	14
35	Ethnic differences in the use of prescription drugs: a cross-sectional analysis of linked survey and administrative data. <i>Open Medicine</i> , 2011, 5, e87-93.	1.5	14
36	High-Cost Users of Prescription Drugs: A Population-Based Analysis from British Columbia, Canada. <i>Health Services Research</i> , 2017, 52, 697-719.	2.0	13

#	ARTICLE	IF	CITATIONS
37	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.6	12
38	Challenges at Care Transitions: Failure to Follow Medication Changes Made at Hospital Discharge. <i>American Journal of Medicine</i> , 2019, 132, 1216-1224.e5.	1.5	11
39	Canadian pharmacare: looking back, looking forward. <i>Healthcare Policy</i> , 2012, 8, 14-23.	0.6	11
40	Use of product listing agreements by Canadian provincial drug benefit plans. <i>Healthcare Policy</i> , 2013, 8, 45-55.	0.6	10
41	Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces. <i>BMC Health Services Research</i> , 2013, 13, 34.	2.2	9
42	Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003590.	8.4	9
43	The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries. <i>PLoS ONE</i> , 2017, 12, e0182742.	2.5	8
44	Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully selected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. <i>BMJ Open</i> , 2017, 7, e015686.	1.9	7
45	A rapidly changing global medicines environment: How adaptable are funding decision-making systems?. <i>Health Policy</i> , 2017, 121, 637-643.	3.0	6
46	Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1001-1008.	1.9	6
47	An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries. <i>Health Policy</i> , 2018, 122, 1012-1017.	3.0	6
48	Toward better prescription drug surveillance in Canada. <i>Cmaj</i> , 2016, 188, E252-E253.	2.0	5
49	The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study. <i>CMAJ Open</i> , 2017, 5, E198-E204.	2.4	5
50	New generic pricing scheme maintains high prices and risks of shortages. <i>Cmaj</i> , 2018, 190, E410-E411.	2.0	5
51	Patterns of borrowing to finance out-of-pocket prescription drug costs in Canada: a descriptive analysis. <i>CMAJ Open</i> , 2018, 6, E544-E550.	2.4	3
52	The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis. <i>Implementation Science</i> , 2017, 12, 141.	6.9	2
53	How to pay for national pharmacare. <i>Cmaj</i> , 2018, 190, E1384-E1388.	2.0	2
54	Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. <i>Health Policy</i> , 2020, 124, 231-238.	3.0	1

#	ARTICLE	IF	CITATIONS
55	A drug by any other nameâ€¦ generic and brand-name drugs are clinically equivalent. Journal of Primary Health Care, 2015, 7, 93.	0.6	0